NCT07075718 Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
| NCT ID | NCT07075718 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Glaukos Corporation |
| Condition | Glaucoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 610 participants |
| Start Date | 2025-06-12 |
| Primary Completion | 2028-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 610 participants in total. It began in 2025-06-12 with a primary completion date of 2028-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Eligibility Criteria
Inclusion Criteria: * Diagnosis of open-angle glaucoma or ocular hypertension in the study eye Exclusion Criteria: * Prior incisional glaucoma surgery in the study eye * Prior argon laser trabeculoplasty (ALT) in the study eye * Prior minimally invasive glaucoma (MIGS) surgery in the study eye
Contact & Investigator
Luis G. Vargas, MD
STUDY CHAIR
Glaukos Corporation
Frequently Asked Questions
Who can join the NCT07075718 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glaucoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07075718 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07075718 currently recruiting?
Yes, NCT07075718 is actively recruiting participants. Contact the research team at ClinicalResearch@glaukos.com for enrollment information.
Where is the NCT07075718 trial being conducted?
This trial is being conducted at Grand Junction, United States, Oklahoma City, United States, El Paso, United States.
Who is sponsoring the NCT07075718 clinical trial?
NCT07075718 is sponsored by Glaukos Corporation. The principal investigator is Luis G. Vargas, MD at Glaukos Corporation. The trial plans to enroll 610 participants.